XML 27 R11.htm IDEA: XBRL DOCUMENT
v3.23.3

Other Income | 12 Months Ended
--- | ---
Sep. 30, 2023
Other Income |
Other Income | Note 4 Other Income Grant income During the year ended September 30, 2023, the Company received $0.5 million (2022: $0 2021: $0.5 million) of a $1.0 million research grant awarded during the year ended September 30, 2021, by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX®2-73 (blarcamesine) related to Parkinson’s disease. The grant income was deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2023, the Company recognized $25,000 (2022: $0; 2021: $54,100) of this grant on its statements of operations within grant income. At September 30, 2023 an amount of $0.9 million (2022: $0.4 million) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statements of operations as the related expenditures are incurred to offset the income. Research and development incentive income Research and development incentive income represents the income earned by Anavex Australia of the Australia R&D credit. This cash incentive is received by Anavex Australia, upon filing of a claim in connection with Anavex Australia’s annual income tax return. During the year ended September 30, 2023, the Company recorded research and development incentive income of $2.7 million (AUD 4.1 million) (2022: $3.3 million (AUD 4.5 million); 2021: $4.5 million (AUD 6.1 million)) in respect of the Australia R&D credit for eligible research and development expenses incurred during the year. This amount is included within Other income (expense) on the consolidated statements of operations. At September 30, 2023, Incentive and tax receivables includes $2.5 million (AUD 3.9 million) (2022: $2.9 million (AUD 4.5 million) relating to Australia R&D credits earned during the year that are expected to be reimbursed upon filing of the Company’s annual claim under this program. The Australia R&D credit program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible (ii) if the specific R&D activities are eligible and (iii) if the individual R&D expenditures have nexus to such R&D activities. The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Anavex Australia is able to continue to claim the R&D tax incentive for as long as it remains eligible and continues to incur eligible research and development expenditures. Although the Company believes that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company’s assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years’ claims already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess penalties and interest on such adjustment. Currently, the Company’s tax incentive claims from 2019 to 2022 are open to potential review by the ATO. Additionally, the period open for review is indefinite if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.

X
- References No definition available. + Details
Name: | avxl_DisclosureOtherIncomeAbstract
Namespace Prefix: | avxl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | avxl_OtherIncomeDisclosureTextBlock
Namespace Prefix: | avxl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration